Capricor Therapeutics (CAPR) Upgraded by Cantor Fitzgerald Amidst FDA Review

Font: Financial Modeling Prep  • Aug 14, 2026

Capricor Therapeutics (NASDAQ: CAPR) Receives Cantor Fitzgerald Upgrade Amidst FDA Review and Financial Strength

• Cantor Fitzgerald upgraded its rating on Capricor Therapeutics to Overweight, signaling positive analyst sentiment.
• Capricor Therapeutics is actively advancing its Biologics License Application (BLA) for deramiocel, with the FDA willing to review amendments and extend the PDUFA date.
• Despite a strong financial position with $238 million in cash, Capricor Therapeutics faces challenges including an FDA advisory committee vote against deramiocel's effectiveness and a securities class-action lawsuit.

Analyst firm Cantor Fitzgerald upgraded its rating on Capricor Therapeutics (NASDAQ: CAPR) to Overweight from Neutral on August 14, 2026. At the time, the stock price was $4.21. Capricor Therapeutics is a biotechnology company developing treatments for rare diseases. Its main product candidate is deramiocel, a potential therapy for Duchenne muscular dystrophy (DMD).

The upgrade follows updates on the company's Biologics License Application (BLA) for deramiocel, which is currently under review by the U.S. Food and Drug Administration (FDA). A BLA is a formal request to market a new biologic drug. Capricor Therapeutics is preparing to amend its application to focus on upper limb skeletal muscle function in patients with DMD.

The FDA has indicated it is willing to review the planned amendment and extend its target action date, known as the PDUFA date. This provides the company more time to submit additional data. This data includes 24-month results from its HOPE-3 study. The company also reports a strong financial position with approximately $238 million in cash and equivalents as of June 30, 2026.

Despite these developments, the company faces challenges. An FDA advisory committee voted 3-9 against finding substantial evidence of deramiocel’s effectiveness. Furthermore, as highlighted by SueWallSt, Capricor Therapeutics is facing a securities class-action lawsuit. The suit alleges that the company did not follow proper trial procedures, which followed a 78.70% drop in stock price from $19.70.